Millicent Patent-Cliff Exposure & CMS Drug Spending Portfolio
Millicent (US): 1 reconciled FDA prescription therapies, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2031-01-01 |
| 2024 CMS Total Public Spend | $5.0M |
| 2024 Medicare Part D Spend | $4.3M |
| 2024 Medicaid Spend | $656K |
| California HCAI SB 17 Filings | 4 WAC filings (max 26.3% 2-yr change) |